{"id":"amisulpride-iv-prevention","safety":{"commonSideEffects":[{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Hyperprolactinemia"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amisulpride selectively antagonizes dopamine D2 and D3 receptors with preferential activity at limbic over striatal regions. In the context of IV prevention, it is being investigated for its potential to modulate immune or inflammatory pathways, though the exact preventive mechanism in this indication requires further clarification from clinical trial data.","oneSentence":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling to prevent or reduce disease progression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:17.196Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of disease progression (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05546359","phase":"PHASE2, PHASE3","title":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2024-01-18","conditions":"Nausea and Vomiting, Postoperative","enrollment":453},{"nctId":"NCT06887621","phase":"PHASE2","title":"Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2025-04-10","conditions":"Post Operative Nausea and Vomiting (PONV)","enrollment":276},{"nctId":"NCT06585540","phase":"PHASE3","title":"A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population","status":"RECRUITING","sponsor":"Benaroya Research Institute","startDate":"2024-09-13","conditions":"Post Operative Nausea and Vomiting","enrollment":100},{"nctId":"NCT05822713","phase":"PHASE3","title":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2023-04-29","conditions":"PONV","enrollment":516},{"nctId":"NCT01857232","phase":"PHASE2","title":"Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-10","conditions":"CINV","enrollment":342},{"nctId":"NCT01991821","phase":"PHASE3","title":"European Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-07","conditions":"PONV","enrollment":368},{"nctId":"NCT02337062","phase":"PHASE3","title":"Phase IIIb Study of APD421 in Combination as PONV Prophylaxis","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-02","conditions":"PONV","enrollment":1147},{"nctId":"NCT01991860","phase":"PHASE3","title":"US Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-08","conditions":"PONV","enrollment":364},{"nctId":"NCT02646566","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2016-03","conditions":"Postoperative Nausea and Vomiting","enrollment":705},{"nctId":"NCT02449291","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (no Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-09","conditions":"Postoperative Nausea and Vomiting","enrollment":568}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amisulpride IV Treatment"],"phase":"phase_3","status":"active","brandName":"Amisulpride IV Prevention","genericName":"Amisulpride IV Prevention","companyName":"Benaroya Research Institute","companyId":"benaroya-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling to prevent or reduce disease progression. Used for Prevention of disease progression (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}